BDBM215552 US9296745, 109-A::US9296745, 109-B::US9296745, 190

SMILES Clc1cnn(c1)C1(CC1)c1nc2ccc(nc2[nH]1)N1CCC[C@H](C1)C(=O)N1CCCC1

InChI Key InChIKey=PZHNKPBYOPQTRG-UHFFFAOYSA-N

Data  7 IC50

  Tab Delimited (TSV)   2D SDfile   Computed 3D by Vconf -m prep SDfile
Find this compound or compounds like it in BindingDB:
   Substructure
Similarity at least:  must be >=0.5
Exact match

Activity Spreadsheet -- Enzyme Inhibition Constant Data from BindingDB

Found 7 hits for monomerid = 215552   

TargetDiacylglycerol O-acyltransferase 2(Human)
Pfizer

US Patent
LigandPNGBDBM215552(US9296745, 109-A | US9296745, 190 | US9296745, 109...)
Affinity DataIC50: 13.8nMpH: 7.4 T: 2°CAssay Description:For determination of IC50 values, the reactions were carried out in 384-well white Polyplates (Perkin Elmer) in a total volume of 20 uL. To 1 uL of c...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/6/2017
Entry Details
Go to US Patent

TargetDiacylglycerol O-acyltransferase 2(Human)
Pfizer

US Patent
LigandPNGBDBM215552(US9296745, 109-A | US9296745, 190 | US9296745, 109...)
Affinity DataIC50: 20.2nMpH: 7.4 T: 2°CAssay Description:For determination of IC50 values, the reactions were carried out in 384-well white Polyplates (Perkin Elmer) in a total volume of 20 uL. To 1 uL of c...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/6/2017
Entry Details
Go to US Patent

TargetDiacylglycerol O-acyltransferase 2(Human)
Pfizer

US Patent
LigandPNGBDBM215552(US9296745, 109-A | US9296745, 190 | US9296745, 109...)
Affinity DataIC50: 35.9nMpH: 7.4 T: 2°CAssay Description:For determination of IC50 values, the reactions were carried out in 384-well white Polyplates (Perkin Elmer) in a total volume of 20 uL. To 1 uL of c...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/6/2017
Entry Details
Go to US Patent

TargetDiacylglycerol O-acyltransferase 2(Human)
Pfizer

US Patent
LigandPNGBDBM215552(US9296745, 109-A | US9296745, 190 | US9296745, 109...)
Affinity DataIC50: 2.10nMAssay Description:For evaluation of the effects of DGAT2 inhibitors in a cell-based setting, cryopreserved human hepatocytes (Lot QOC, Celsis, Chicago, Ill.) were thaw...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/6/2017
Entry Details
Go to US Patent

TargetDiacylglycerol O-acyltransferase 2(Human)
Pfizer

US Patent
LigandPNGBDBM215552(US9296745, 109-A | US9296745, 190 | US9296745, 109...)
Affinity DataIC50: 5.5nMAssay Description:For evaluation of the effects of DGAT2 inhibitors in a cell-based setting, cryopreserved human hepatocytes (Lot QOC, Celsis, Chicago, Ill.) were thaw...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/6/2017
Entry Details
Go to US Patent

TargetDiacylglycerol O-acyltransferase 2(Human)
Pfizer

US Patent
LigandPNGBDBM215552(US9296745, 109-A | US9296745, 190 | US9296745, 109...)
Affinity DataIC50: 1.30nMAssay Description:Inhibition of human DGAT2 assessed as reduction in synthesis of triglycerol in human hepatocyte using [14C]glycerol as substrate preincubated for 20 ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/27/2019
Entry Details Article
PubMed
TargetDiacylglycerol O-acyltransferase 2(Human)
Pfizer

US Patent
LigandPNGBDBM215552(US9296745, 109-A | US9296745, 190 | US9296745, 109...)
Affinity DataIC50: 14nMAssay Description:Inhibition of human DGAT2 using [1-14C]decanoyl-CoA/1,2-didecanoyl-sn-glycerol as substrate preincubated for 120 mins followed by substrate addition ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/27/2019
Entry Details Article
PubMed